The platinum analogues, cisplatin and carboplatin, are among the most widely used
chemotherapeutic agents in oncology. Both agents have a broad spectrum of clinical activity …

Background Introduced into clinical usage in 1992 as a platinum analogue with a
distinctively different toxicity profile from cisplatin, carboplatin has become a commonly …

It all started with an accidental discovery in the laboratory of Dr. Barnet Rosenberg at
Michigan State University in the mid 1960s. Now, thirty years from the landmark publication …

Cisplatin: Current Status and New Developments is a collection of papers presented at a
symposium sponsored by the University of Alabama in Birmingham Comprehensive Cancer …

Cisplatin plays a central role in cancer chemotherapy in spite of its toxicity. To circumvent
this toxicity and to enhance its therapeutic index a lot of preclinical and clinical studies have …

The platinum agents (cisplatin, carboplatin and oxaliplatin) are among the most useful
anticancer agents available to oncologists. The drugs have the potential to produce both …

During the past decade more than a dozen derivatives of cisplatin have reached the stage of
clinical development. Carboplatin(cis-diammine-cyclobutane, dicarboxylato platinum II …

The platinum drugs represent a unique and important class of antitumor agents. The initial
discovery of the antitumor properties of cisplatin by Dr. Barnett Rosenberg was quickly …

Since the introduction of platinum-based combination chemotherapy, particularly cisplatin,
the outcome of the treatment of many solid tumours has changed. The leading platinum …

The accidental discovery of the anticancer properties of cisplatin and its clinical introduction
in the 1970s represent a major landmark in the history of successful anticancer drugs …